impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Paediatric Rheumatology

 

Uveitis treatment in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: response to tumour necrosis factor inhibitors

1, 2, 3, 4

 

  1. Division of Pediatric Rheumatology, Allergy and Immunology, Department of Pediatrics, University of Minnesota, MN, USA. riskalla@umn.edu
  2. Amgen Inc., Thousand Oaks, CA, USA.
  3. Clinical and Translational Science Institute, University of Minnesota, MN, USA.
  4. Division of Rheumatology, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, PA, USA.

the CARRA Registry investigators

CER17763
2025 Vol.43, N°5
PI 0946, PF 0952
Paediatric Rheumatology

Free to view
(click on article PDF icon to read the article)

PMID: 39711401 [PubMed]

Received: 10/04/2024
Accepted : 30/10/2024
In Press: 20/12/2024
Published: 08/05/2025

Abstract

OBJECTIVES:
Treatment with tumour necrosis factor inhibitors (TNFi) has significantly improved outcomes in uveitis associated with juvenile idiopathic arthritis (JIA-U). This study examines a CARRA Registry cohort of JIA-U patients on TNFi to analyse utilisation patterns and identify factors associated with response.
METHODS:
This retrospective cohort study used CARRA Registry data for subjects aged 0–25 with JIA-U who had uveitis onset before the age of 19, and ever used TNFi. We collected data about demographics, uveitis courses, and treatment. We defined TNFi response and identified associated characteristics. As appropriate, comparisons between factors were tested using t-test, Chi-square, and Fisher’s exact test. Multivariable logistic regression was used to model TNFi response.
RESULTS:
Among 871 JIA-U subjects, 616 (70.7%) used TNFi; 558 met inclusion criteria; 418 (74.9%) had successful treatment under TNFi. Among the 140 (25.1%) TNFi non-responders, 117 remained on TNFi and 23 discontinued. Multivariate analysis found significant TNFi success associations with White race (OR=2.08, p=0.005) and non-oligoarticular JIA (OR=1.58, p=0.044).
CONCLUSIONS:
In this CARRA Registry cohort of patients with JIA-U, a large proportion used a TNFi for uveitis. The percentage successfully treated with TNFi is consistent with the current literature. White race and non-oligoarticular JIA were associated with a successful response to TNFi.

DOI: https://doi.org/10.55563/clinexprheumatol/08z0v4

Rheumatology Article